The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Sandoz is seeking an injunction preventing ... as competition from other products have reduced Amgen’s market share for the product. Between 1998 and 2004, Enbrel was approved in the U.S ...

Sandoz CEO Richard Saynor has reportedly stated that the proposal to introduce a Europe-wide list price for new medicines is ...

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

“Because of [our] credentials of being first to market with many biosimilars and generic products, we were selected by Sandoz to do this transaction in Colombia,” he explained. “They decided ...

Sandoz dials up product launch plans ahead of market debut Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of ...

[7,8] Sandoz is the leading biosimilar provider globally and has recently moved up to third position in the US, with a strategic ambition to occupy the leading position in that market.[9] The ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit ... prevented would-be competitors from entering the U.S. product market for etanercept in violation of the Sherman Act.

The company’s Financial Health Score of "GOOD" further reinforces its stable market position. Notably, Sandoz is preparing for significant product launches in 2025, including Doneotumab and ...